SE0000698L - - Google Patents

Info

Publication number
SE0000698L
SE0000698L SE0000698A SE0000698A SE0000698L SE 0000698 L SE0000698 L SE 0000698L SE 0000698 A SE0000698 A SE 0000698A SE 0000698 A SE0000698 A SE 0000698A SE 0000698 L SE0000698 L SE 0000698L
Authority
SE
Sweden
Prior art keywords
medicament
extract
leaves
patient
give
Prior art date
Application number
SE0000698A
Other languages
English (en)
Other versions
SE0000698D0 (sv
SE516468C2 (sv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to SE0000698A priority Critical patent/SE516468C2/sv
Publication of SE0000698D0 publication Critical patent/SE0000698D0/xx
Priority to AU2001241315A priority patent/AU2001241315A1/en
Priority to DE60108227T priority patent/DE60108227D1/de
Priority to EP01912627A priority patent/EP1261358B1/de
Priority to AT01912627T priority patent/ATE286402T1/de
Priority to PCT/SE2001/000447 priority patent/WO2001064231A1/en
Publication of SE0000698L publication Critical patent/SE0000698L/xx
Publication of SE516468C2 publication Critical patent/SE516468C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0000698A 2000-03-02 2000-03-02 Användning av ett extrakt från Morinda citrifolia L. för framställning av läkemedel för behandling av tinnitus. SE516468C2 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0000698A SE516468C2 (sv) 2000-03-02 2000-03-02 Användning av ett extrakt från Morinda citrifolia L. för framställning av läkemedel för behandling av tinnitus.
AU2001241315A AU2001241315A1 (en) 2000-03-02 2001-03-02 Use of a composition
DE60108227T DE60108227D1 (de) 2000-03-02 2001-03-02 Verwendung von morinda citrifolia zur behandlung von tinnitus
EP01912627A EP1261358B1 (de) 2000-03-02 2001-03-02 Verwendung von morinda citrifolia zur behandlung von tinnitus
AT01912627T ATE286402T1 (de) 2000-03-02 2001-03-02 Verwendung von morinda citrifolia zur behandlung von tinnitus
PCT/SE2001/000447 WO2001064231A1 (en) 2000-03-02 2001-03-02 Use of a composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000698A SE516468C2 (sv) 2000-03-02 2000-03-02 Användning av ett extrakt från Morinda citrifolia L. för framställning av läkemedel för behandling av tinnitus.

Publications (3)

Publication Number Publication Date
SE0000698D0 SE0000698D0 (sv) 2000-03-02
SE0000698L true SE0000698L (de) 2001-09-03
SE516468C2 SE516468C2 (sv) 2002-01-15

Family

ID=20278673

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000698A SE516468C2 (sv) 2000-03-02 2000-03-02 Användning av ett extrakt från Morinda citrifolia L. för framställning av läkemedel för behandling av tinnitus.

Country Status (6)

Country Link
EP (1) EP1261358B1 (de)
AT (1) ATE286402T1 (de)
AU (1) AU2001241315A1 (de)
DE (1) DE60108227D1 (de)
SE (1) SE516468C2 (de)
WO (1) WO2001064231A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737089B2 (en) * 1999-08-27 2004-05-18 Morinda, Inc. Morinda citrifolia (Noni) enhanced animal food product
US7244463B2 (en) 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US8790727B2 (en) 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
US7442395B2 (en) 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
EP4299059A1 (de) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Zusammensetzung zur behandlung von tinnitus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409144A (en) * 1978-01-19 1983-10-11 Research Corporation Of The University Of Hawaii Xeronine, a new alkaloid, useful in medical, food and industrial fields
US5288491A (en) * 1992-09-24 1994-02-22 Herbert Moniz Noni (Morinda Citrifolia) as a pharmaceutical product

Also Published As

Publication number Publication date
SE0000698D0 (sv) 2000-03-02
ATE286402T1 (de) 2005-01-15
AU2001241315A1 (en) 2001-09-12
EP1261358A1 (de) 2002-12-04
DE60108227D1 (de) 2005-02-10
SE516468C2 (sv) 2002-01-15
EP1261358B1 (de) 2005-01-05
WO2001064231A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
JP3388117B2 (ja) カイガンショウ抽出物に基づく血小板反応性調節剤の調製方法
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
WO2004112711A3 (en) Oral extended-release composition
RU2001122719A (ru) Композиция для лечения от ожирения и способ эстетической терапии
Jia et al. Why bortezomib cannot go with ‘green’?
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
IL192137A (en) Formulations useful in the treatment of male and female impotence
WO2006089312A3 (en) Orally bioavailable cci-779 tablet formulations
SE0000698L (de)
NO20044855L (no) Formuleringer anvendelige ved behandling av mannlig og kvinnelig impotents
MY137516A (en) Pharmaceutical composition comprising lumiracoxib
TNSN07474A1 (en) Dosage regimen for prasugrel
JP2011513340A5 (de)
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
IT1314199B1 (it) Composizioni contenenti sostanze ad attivita' adrenergica ed estrattivegetali per il trattamento del sovrappeso e obesita'
CN101890102A (zh) 野花椒根皮或茎皮提取物及其提取方法和口腔药用组合物
JP2002515439A5 (de)
CA2396209A1 (en) The use of mirtazapine for the treatment of sleep disorders
KR20010009465A (ko) 금단증상을 억제하는 조성물
WO2001054676A3 (de) Formulierungen bei dehydratationszuständen
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
DE50005714D1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
UA91028C2 (ru) Использование лавандового масла для профилактики и лечения соматических расстройств и посттравматического стресса

Legal Events

Date Code Title Description
NUG Patent has lapsed